Diabetic nephropathy. Insulin-dependent diabetes mellitus with renal complications
Conditions
Interventions
Intervention 1: Intervention group: Atorvastatin 10 mg per day will be administered to the patients in intervention group for 90 days. At the end of the third month, patients will be asked not to use
Treatment - Drugs
Placebo
Intervention group: Atorvastatin 10 mg per day will be administered to the patients in intervention group for 90 days. At the end of the third month, patients will be asked not to use Atorvastatin for
Control group: Daily Placebo will be administered to the patients in control group for 90 days. At the end of the third month, patients will be asked not to use placebo for a month.
Sponsors
Vice chancellor for research, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients between 20 to 65 years old; patients with type 2 diabetes mellitus; history of gestational diabetes mellitus; proteinuria levels lower than 3 g/d (nephrotic range); estimated glomerular filtration rate more than 30 mL/min/1.73m2 Exclusion criteria: use of fibrates, statins antagonists, aspirin, allopurinol, ß-blockers, pentoxifylline, fish oil, other antioxidant drugs consumption in past 6 months; active smoking; active coronary artery disease in the previous 6 months; diabetic foot; hepatitis; poorly controlled diabetes (Hb-A1c more than 7.5%)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipid profile. Timepoint: Before intervention, 90 days after intervention initiation. Method of measurement: Blood samlple.;Serum creatinine. Timepoint: Before intervention, 90 days after intervention initiation. Method of measurement: Blood samlple.;Serum uric acid. Timepoint: Before intervention, 90 days after intervention initiation. Method of measurement: Blood samlple.;Urine Protein. Timepoint: Before intervention, 90 days after intervention initiation. Method of measurement: Blood samlple. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Parviz Saleh
Emam Reza educational-medical center
Outcome results
None listed